Cannabinoids and appetite: Food craving and food pleasure

International Review of Psychiatry

Volumn 21, Issue 2 SPEC. ISS., 2009, Pages 163-171

  Kirkham, Tim C ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; CANNABINOID; CANNABINOID 1 RECEPTOR ANTAGONIST; DRONABINOL; ENDOCANNABINOID; NABILONE; NALOXONE; OPIATE ANTAGONIST; RIMONABANT;

ANOREXIA NERVOSA; APPETITE; APPETITE DISORDER; CLINICAL TRIAL; DRUG MECHANISM; DRUG POTENTIATION; EATING DISORDER; FOOD INTAKE; HUMAN; HYPERPHAGIA; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW;

ANIMALS; APPETITE; BRAIN; CANNABINOIDS; ENDOCANNABINOIDS; FEEDING BEHAVIOR; HUMANS; MOTIVATION; RECEPTORS, CANNABINOID;

EID: 67651065803     PISSN: 09540261     EISSN: 13691627     Source Type: Journal    
DOI: 10.1080/09540260902782810     Document Type: Review

References (82)

1. Arnone, M., Maruani, J., Chaperon, F., Thiebot, M.H., Poncelet, M., Soubrie, P., & Le Fur, G. (1997). Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology (Berlin), 132, 104-106. (Pubitemid 27303746)
2. Artmann, A., Petersen, G., Hellgren, L.I., Boberg, J., Skonberg, C., Nellemann, C., Hansen, S.H., & Hansen, H.S. (2008). Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine. Biochimica et Biophysica Acta, 1781(4), 200-212.
3. Avraham, Y., Ben Menachem, A., Okun, A., Zlotarav, O., Abel, N., Mechoulam, R., & Berry, E.M. (2005). Effects of the endocannabinoid noladin ether on body weight, food consumption, locomotor activity, and cognitive index in mice. Brain Research Bulletin, 65, 117-123. (Pubitemid 40348796)
4. Beal, J. E., Olson, R., Laubenstein, L., Morales, J. O., Bellman, P., Yangco, B., Lefkowitz, L., Plasse, T.F., & Shepard, K.V. (1995). Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. Journal of Pain Symptom Management, 10, 89-97.
5. Berger, A., Crozier, G., Bisogno, T., Cavaliere, P., Innis, S., & Di Marzo, V. (2001). Anandamide and diet: Inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets. Proceedings of the National academy of Sciences USA, 98(11), 6402-6406. (Pubitemid 32488249)
6. Berridge, K. C. (2007). Brain reward systems for food incentives hedonics in normal appetite and eating disorders. In T. C. Kirkham & S. J. Cooper (Eds.), Appetite and body weight: Integrative systems and the development of anti-obesity drugs. Burlington, MA: Academic Press.
7. Blundell, J. E., Jebb, S. A., Stubbs, R. J. Gross, H., Ebert, M.H., Faden, V.B., Goldberg, S.C., Kaye, W.H., Caine, E.D., Hawks, R., and Zinberg, N. (1983). A double-blind trial of delta 9-tetrahydrocannabinol in primary anorexia nervosa. Journal of Clinical Psychopharmacology, 3, 165-171.
8. Bodnar, R. J. (2004). Endogenous opioids and feeding behavior: A 30-year historical perspective. Peptides, 25, 697-725.
9. Chen, R., Huang, R., Shen, C., Chen, C.P., MacNeil, D.J., & Fong, T.M. (2004). Synergistic effects of cannabinoid inverse agonist AM251 and opioid antagonist nalmefene on food intake in mice. Brain Research and Brain Research Reviews, 999, 227-230. (Pubitemid 38167397)
10. Chopra, I.C., & Chopra, R.N. (1957). The use of the cannabis drugs in India. Bulletin on Narcotics, 9, 4-29.
11. Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H., & Astrup, A. (2007). Efficacy and safety of the weight-loss drug rimonabant: A meta-analysis of randomised trials. Lancet, 370, 1706-1713. (Pubitemid 350100788)
12. Colombo, G., Agabio, R., Diaz, G., Lobina, C., Reali, R., & Gessa, G.L. (1998). Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Science, 63, PL113-117. (Pubitemid 28378339)
13. Cooper, S. J., & Kirkham, T. C. (1993). Opioid mechanisms in the control of food consumption and taste preferences. In A. Herz, H. Akil & E. J. Simon (Eds.), Handbook of Experimental Pharmacology, Vol.104, part II. Berlin: Springer-Verlag.
14. Cota, D., Marsicano, G., Tschop, M., Grubler, Y., Flachskamm, C., Schubert, M. et al. (2003). The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. Journal of Clinical Investigation, 112, 423-431. (Pubitemid 38063771)
15. Di Marzo, V., Sepe, N., De Petrocellis, L., Berger, A., Crozier, G., Fride, E., & Mechoulam, R. (1998). Trick or treat from food endocannabinoids? Nature, 396(6712), 636-637.
16. Di Marzo, V., & Matias, I. (2005). Endocannabinoid control of food intake and energy balance. Nature Neuroscience, 8, 585-589. (Pubitemid 40594198)
17. Di Marzo, V. (2008). The endocannabinoid system in obesity and type 2 diabetes. Diabetologia, 51, 1356-1367.
18. Di Patrizio, N. V., & Simansky, K. J. (2008). Activating parabrachial cannabinoid CB1 receptors selectively stimulate feeding of palatable foods in rats. Journal of Neuroscience, 28, 9702-9709.
19. Drewnowski, A., Krahn, D. D., Demitrack, M. A., Nairn, K., & Gosnell, B.A. (1992). Taste responses and preferences for sweet high-fat foods: Evidence for opioid involvement. Physiology & Behavior, 51, 371-379.
20. Fride, E. (2008). Multiple roles for the endocannabinoid system during the earliest stages of life: Pre- and postnatal development. Journal of Neuroendocrinology, 20(Suppl.1), S75-81.
21. Fride, E., Bregman, T., & Kirkham, T.C. (2005). Endocannabinoids and food intake: Newborn suckling and appetite regulation in adulthood. Experimental Biology and Medicine (Maywood), 230(4), 225-234. (Pubitemid 40478246)
22. Gaoni, Y., & Mechoulam, R. (1971). The isolation and structure of delta-1-tetrahydrocannabinol and other neutral cannabinoids from hashish. Journal of the American Chemistry Society, 93, 217-224.
23. Gallate, J., & McGregor, I. (1999). The motivation for beer in rats: Effects of ritanserin, naloxone and SR 141716. Psychopharmacology, 142, 302-308. (Pubitemid 29200158)
24. Gallate, J., Saharov, T., Mallet, P., & McGregor, I.S. (1999). Increased motivation for beer in rats following administration of a cannabinoid CB1 receptor agonist. European Journal of Pharmacology, 370, 233-240. (Pubitemid 29192867)
25. Gazzerro, P., Caruso, M. G., Notarnicola, M., Misciagna, G., Guerra, V., Laezza, C., & Bifulco, M. (2007). Association between cannabinoid type-1 receptor polymorphism and body mass index in a southern Italian population. International Journal of Obesity (London), 31(6), 908-912. (Pubitemid 46842680)
26. Gomez, R., Navarro, M., Ferrer, B., Trigo, J.M., Bilbao, A., Del Arco, I., Cippitelli, A., Nava, F., Piomelli, D., & Rodriguez de Fonseca, F. (2002). A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. Journal of Neuroscience, 22, 9612-9617.
27. Gross, H., Ebert, M.H., Faden, V.B., Goldberg, S.C., Kaye, W.H., Caine, E.D., Hawks, R., & Zinberg, N. (1983). A double-blind trial of delta 9-tetrahydrocannabinol in primary anorexia nervosa. Journal of Clinical Psychopharmacology, 3, 165-171. (Pubitemid 12166024)
28. Haney, M., Rabkin, J., Gunderson, E., & Foltin, R. W. (2005). Dronabinol and marijuana in HIV+ marijuana smokers: Acute effects on caloric intake and mood. Psychopharmacology (Berlin), 181, 170-178. (Pubitemid 41440928)
29. Hao, S., Avraham, Y., Mechoulam, R., & Berry, E.M. (2000). Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice. European Journal of Pharmacology, 392, 147-156. (Pubitemid 30184903)
30. Harrold, J., Elliott, C., King, P., Widowson, P.S., & Williams, G. (2002). Down-regulation of cannabinoid-1 (CB-1) receptors in specific extrahypothalamic regions of rats with dietary obesity: A role for endogenous cannabinoids in driving appetite for palatable food? Brain Research, 952, 232-238.
31. Higgs, S., Williams, C. M., & Kirkham, T. C. (2003). Cannabinoid influences on palatability: Microstructural analysis of sucrose drinking after delta(9)-tetrahydrocannabinol, anandamide, 2-arachidonoyl glycerol and SR141716. Psychopharmacology (Berlin), 165, 370-377.
32. Hildebrandt, A. L., Kelly-Sullivan, D. M., & Black, S. C. (2003). Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice. European Journal of Pharmacology, 462, 125-132. (Pubitemid 36183743)
33. Jaeger, J. P., Mattevi, V. S., Callegari-Jacques, S. M., & Hutz, M. H. (2008). Cannabinoid type-1 receptor gene polymorphisms are associated with central obesity in a Southern Brazilian population. Disease Markers, 25(1), 67-74.
34. Jamshidi, N., & Taylor, D. (2001). Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. British Journal of Pharmacology, 134, 1151-1154. (Pubitemid 33097243)
35. Jarrett, M. M., Scantlebury, J., & Parker, L. A. (2007). Effect of delta(9)-tetrahydrocannabinol on quinine palatability and AM251 on sucrose and quinine palatability using the taste reactivity test. Physiology & Behavior, 90, 425-430.
36. Jarrett, M. M., Limebeer, C. L., & Parker, L. A. (2005). Effect of Delta9-tetrahydrocannabinol on sucrose palatability as measured by the taste reactivity test. Physiology & Behavior, 86, 475-479.
37. Kirkham, T. C. (2005). Endocannabinoids in the regulation of appetite and body weight. Behavioural Pharmacology, 16, 297-313. (Pubitemid 41404803)
38. Kirkham, T. C. (1990). Enhanced anorectic potency of naloxone in rats sham feeding 30% sucrose: Reversal by repeated naloxone administration. Physiology & Behavior, 47, 419-426.
39. Kirkham, T. C., Williams, C. M., Fezza, F., & Di Marzo, V. (2002). Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: Stimulation of eating by 2-arachidonoyl glycerol. British Journal of Pharmacology, 136, 550-557. (Pubitemid 34717699)
40. Kirkham, T. C., & Williams, C. M. (2001a). Endocannabinoids: Neuromodulators of food craving?. In M. Hetherington (Ed.) Food Cravings and Addiction. Surrey, UK: Leatherhead Publishing.
41. Kirkham, T. C., & Williams, C. M. (2001b). Synergistic effects of opioid and cannabinoid antagonists on food intake. Psychopharmacology (Berlin), 153, 267-270.
42. Kirkham, T. C., & Cooper, S. J. (1988). Naloxone attenuation of sham feeding is modified by manipulation of sucrose concentration. Physiology & Behavior, 44, 491-494. (Pubitemid 19030109)
43. Mahler, S. V., Smith, K. S., & Berridge, K. C. (2007). Endocannabinoid hedonic hotspot for sensory pleasure: Anandamide in nucleus accumbens shell enhances 'liking' of a sweet reward. Neuropsychopharmacology, 32, 2267-2278.
44. Marín Bivens, C. L., Thomas, W. J., & Stanley, B. G. (1998). Similar feeding patterns are induced by perifornical neuropeptide Y injection and by food deprivation. Brain Research, 782, 271-280.
45. Matias, I., Cristino, L., & di Marzo, V. (2008). Endocannabinoids: Some like it fat (and sweet too). Journal of Neuroendocrinol, 20(Suppl.1), 100-109. (Pubitemid 351552684)
46. Melis, T., Succu, S., Sanna, F., Boi, A., Argiolas, A., & Melis, M. R. (2007). The cannabinoid antagonist SR 141716A (Rimonabant) reduces the increase of extracellular dopamine release in the rat nucleus accumbens induced by a novel high palatable food. Neuroscience Letters, 419, 231-235. (Pubitemid 46755483)
47. Miller, C. C., Murray, T. F., Freeman, K. G., & Edwards, G. L. (2004). Cannabinoid agonist, CP 55,940, facilitates intake of palatable foods when injected into the hindbrain. Physiology & Behavior, 80, 611-616.
48. Monteleone, P., Matias, I., Martiadis, V., De Petrocellis, M., Maj, M., & Di Marzo, V. (2005). Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. Neuropsychopharmacology, 30(6), 1216-1221. (Pubitemid 40720981)
49. Osei-Hyiamen, D., DePetrillo, M., Pacher, P., Liu, J., Radaeva, S., Batkai, S., Harvey-White, J., Mackie, K., Offertaler, L., Wang, L., & Kunos, G. (2005). Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. Journal of Clinical Investigation, 115, 1298-1305. (Pubitemid 40629049)
50. Pecina, S., & Berridge, K. C. (2000). Opioid site in nucleus accumbens shell mediates eating and hedonic 'liking' for food: Mmap based on microinjection Fos plumes. Brain Research, 863, 71-86.
51. Pério, A., Barnouin, M. C., Poncelet, M., & Soubrié, P. (2001). Activity of SR141716 on post-reinforcement pauses in operant responding for sucrose reward in rats. Behavioural Pharmacology, 12, 641-645.
52. Plasse, T. F., Gorter, R. W., Krasnow, S. H., Lane, M., Shepard, K. V., & Wadleigh, R. G. (1991). Recent clinical experience with dronabinol. Pharmacological Biochemistry Behaviour, 40, 695-700.
53. Poncelet, M., Maruani, J., Calassi, R., & Soubrié, P. (2003). Overeating, alcohol and sucrose consumption decrease in CB1 receptor deleted mice. Neuroscience Letters, 343, 216-218. (Pubitemid 38365988)
54. Ravinet-Trillou, C., Arnone, M., Delgorge, C., Gonalons, N., Keane, P., Maffrand, J. P., & Soubrié, P. (2003). Antiobesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. American Journal of Physiological Reguluation Integral and Comparative Physiology, 284, R345-353. (Pubitemid 36120150)
55. Rodriguez de Fonseca, F., Navarro, M., Gómez, R., Escuredo, L., Nava, F., Fu, J. et al. (2001). An anorexic lipid mediator regulated by feeding. Nature, 414(6860), 209-212. (Pubitemid 33051235)
56. Russo, P., Strazzullo, P., Cappuccio, F. P., Tregouet, D. A., Lauria, F., Loguercio, M., Barba, G., Versiero, M., & Siani, A. (2007). Genetic variations at the endocannabinoid type 1 receptor gene (CNR1) are associated with obesity phenotypes in men. Journal of Clinical Endocrinology and Metabolism, 92(6), 2382-2386. (Pubitemid 46997151)
57. Sanchis-Segura, C., Cline, B., Marsicano, G., Lutz, B., & Spanagel, R. (2004). Reduced sensitivity to reward in CB1 knockout mice. Psychopharmacology (Berlin), 176, 223-232. (Pubitemid 39517952)
58. Scheen, A. J., Van Gaal, L. G., Despres, J. P., Pi-Sunyer, X., Golay, A., & Hanotin, C. (2006). Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: Overview of RIO studies. Reviews in Medical Suisse, 2, 1916-1923. (Pubitemid 44432614)
59. Siegfried, Z., Kanyas, K., Latzer, K., Latzer, T., Karni, O., Bloch, M., Lerer, B., & Berry, E. M. (2004). Association study of cannabinoid receptor gene (CNR1) alleles and anorexia nervosa: Differences between restricting and bingeing/purging subtypes. American Journal of Medical Genetics B, 125B, 126-130. (Pubitemid 38141416)
60. Simiand, J., Keane, M., Keane, P., & Soubrié, P. (1998). SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behavioural Pharmacology, 9, 179-181. (Pubitemid 28186515)
61. Sipe, J. C., Waalen, J., Gerber, A., & Beutler, E. (2005). Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH). International Journal of Obesity (London), 29(7), 755-759. (Pubitemid 40897010)
62. Solinas, M., Goldberg, S. R., & Piomelli, D. (2008). The endocannabinoid system in brain reward processes. British Journal of Pharmacology, 154, 369-383. (Pubitemid 351670594)
63. Solinas, M., Justinova, Z., Goldberg, S. R., & Tanda, G. (2006). Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nuclear accumbens shell in rats. Journal of Neurochemistry, 98, 408-419. (Pubitemid 44133146)
64. Solinas, M., & Goldberg, S. R. (2005). Motivational effects of cannabinoids and opioids on food reinforcement depend on simultaneous activation of cannabinoid and opioid systems. Neuropsychopharmacology, 30, 2035-2045. (Pubitemid 43093503)
65. Solinas, M., Zangen, A., Thiriet, N., & Goldberg, S. R. (2004). Beta-endorphin elevations in the ventral tegmental area regulate the discriminative effects of Delta-9-tetrahydrocannabinol. European Journal of Neuroscience, 19, 3183-3192. (Pubitemid 38859535)
66. Soria-Gomez, E., Matias, I., Rueda-Orozco, P. E., Cisneros, M., Petrosino, S., Navarro, L., Di Marzo, V., & Prospéro-García, O. (2007). Pharmacological enhancement of the endocannabinoid system in the nucleus accumbens shell stimulates food intake and increases c-Fos expression in the hypothalamus. British Journal of Pharmacology, 151, 1109-1116. (Pubitemid 47195529)
67. Stratford, T. R. (2007). The nucleus accumbens shell as a model of integrative subcortical forebrain systems regulating food intake. In T. C. Kirkham & S. J. Cooper (Eds.), Appetite and body weight: Integrative systems and the development of antiobesity drugs. Burlington, MA: Academic Press.
68. Tallett, A. J., Blundell, J. E., & Rodgers, J. R. (2007a). Grooming, scratching and feeding: Role of response competition in acute anorectic response to rimonabant in male rats. Psychopharmacology (Berlin), 195, 27-39.
69. Tallett, A. J., Blundell, J. E., & Rodgers, J. R. (2007b). Acute anorectic response to cannabinoid CB1 receptor antagonist/ inverse agonist AM 251 in rats: Indirect behavioural mediation. Behavioural Pharmacology, 18, 591-600.
70. Tart, C. (1970). Marijuana intoxication: Common experiences. Nature, 226, 701-704.
71. Tucci, S. A., Rogers, E. K., Korbonits, M., & Kirkham, T. C. (2004). The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin. British Journal of Pharmacology, 143(5), 520-523. (Pubitemid 39524268)
72. van der Stelt, M., & Di Marzo, V. (2003). The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: Implications for neurological and psychiatric disorders. European Journal of Pharmacology, 480, 133-150.
73. Van Gaal, L., Pi-Sunyer, X., Despres, J.-P., McCarthy, C., & Scheen, A. (2008). Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients. Pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care, 31(Suppl.2), S229-S240.
74. Vickers, S., Webster, L., Wyatt, A., Dourish, C. T., & Kennett, G. A. (2003). Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology (Berlin), 167, 103-111. (Pubitemid 36535298)
75. Volicer, L., Stelly, M., Morris, J., McLaughlin, J., & Volicer, B. J. (1997). Effects of dronabinol on anorexia and disturbed behaviour in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry, 12, 913-919. (Pubitemid 27420571)
76. Werner, N., & Koch, J. (2003). Effects of the cannabinoid antagonists AM281 and AM630 on deprivation-induced intake in Lewis rats. Brain Research, 967, 290-292. (Pubitemid 36329164)
77. Williams, C. M., & Kirkham, T. C. (2002a). Reversal of delta 9-THC hyperphagia by SR141716 and naloxone but not dexfenfluramine. Pharmacology Biochemistry and Behavior, 71, 333-340.
78. Williams, C. M., & Kirkham, T. C. (2002b). Observational analysis of feeding induced by Delta9-THC and anandamide. Physiological Behavaviour, 76, 241-250.
79. Williams, C. M., Rogers, P. J., & Kirkham, T. C. (1998). Hyperphagia in pre-fed rats following oral delta9 THC. Physiological Behaviour, 65, 343-346.
80. Williams, C. M., & Kirkham, T. C. (1999). Anandamide induces overeating: Mediation by central cannabinoid (CB1) receptors. Psychopharmacology (Berlin), 143, 315-317.
81. Yeomans, M. R. (2007). The role of palatability in control of human appetite: Implications for understanding and treating obesity. In T. C. Kirkham & S. J. Cooper (Eds.), Appetite and body weight: Integrative systems and the development of anti-obesity drugs. Burlington, MA: Academic Press.
82. Yeomans, M. R., & Gray, R. W. (1996). Selective effects of naltrexone on food pleasantness and intake. Physiological Behaviour, 60, 439-446. (Pubitemid 26274284)